Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

SANOFI : Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/22/2013 | 01:09am EDT

PRESS RELEASE

Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe - Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 pediatric vaccine - Lyon, France - April 22, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN

and NYSE: SNY), announced today that the European Commission approved Sanofi Pasteur's 6-in-
1 pediatric vaccine HexyonTM/Hexacima® (DTaP-IPV-Hib-HepB vaccine) for primary and booster vaccination of infants from six weeks of age.
HexyonTM/Hexacima® is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
The new vaccine will be commercialized under the brand name HexyonTM in Western European countries* by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima® in Eastern European countries by Sanofi Pasteur.

"Hexyon/Hexacima ready-to-use, 6-in-1 pediatric vaccine will raise the standard of care of vaccination for millions of children. It reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur. "We will introduce Hexyon/Hexacima vaccine in countries that are looking for improved and effective solutions for public immunization programs."

Key benefits of HexyonTM/Hexacima® vaccine:

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
04/15SANOFI AVENTIS : Board of Directors meeting of Sanofi-Aventis Pakistan Limited
AQ
04/11SANOFI : Health Canada issues Notice of Compliance with Conditions (NOC/c) for L..
AQ
04/10SANOFI : Disclosure of trading in own shares
AQ
04/10Sanofi to cut U.S. insulin costs for some patients to $99 per month
RE
04/10SANOFI : provides unprecedented access to its insulins for one set monthly price
PR
04/10ALNYLAM PHARMACEUTICALS : inks broad R&D deal with Regeneron
AQ
04/09SANOFI : boosts pharma logistics capacity in Dubai with Kuehne + Nagel
AQ
04/09SANOFI : and Alnylam conclude research phase of RNAi alliance
AQ
04/09SANOFI : and Alnylam conclude research and option phase of 2014 rare disease all..
AQ
04/08Sanofi and Alnylam conclude research and option phase of 2014 rare disease al..
GL
More news
Financials (€)
Sales 2019 36 138 M
EBIT 2019 9 202 M
Net income 2019 5 015 M
Debt 2019 14 050 M
Yield 2019 4,36%
P/E ratio 2019 16,67
P/E ratio 2020 14,69
EV / Sales 2019 2,91x
EV / Sales 2020 2,71x
Capitalization 91 189 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 83,6 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-3.44%103 044
JOHNSON & JOHNSON6.95%367 516
ROCHE HOLDING LTD.10.56%230 795
PFIZER-6.25%227 180
NOVARTIS8.84%205 463
MERCK AND COMPANY1.51%200 343